• Chronic Pain
  • Contact
  • Depression
  • Home
  • Privacy Policy
  • PTSD
  • Terms and Conditions
  • Video
Tuesday, February 7, 2023
  • Login
ketamine.news
Advertisement
  • Home
  • Depression
    ketamine news

    Bronner’s Magic Soaps Becomes The First Company to Offer Ketamine-Assisted Therapy as Part of Employees’ Health Benefits

    ketamine news

    Popular Soap Company–Dr. Bronner’s– Plans To Explore The Psychedelic Space

    ketamine news

    Psychedelic and Plant Medicine Decriminalization Efforts Spread to the Midwest.

    ketamine news

    What There is to Know About Ketamine vs. Electroconvulsive Therapy (ECT)

    ketamine news

    Dispelling the Stigmas, Ketamine, and the Future of Mental Healthcare

    ketamine news

    A First of its Kind: Wellbeing Digital Sciences Delivers its “First Ketamine Treatment Under the Inpatient KITE Program”

    ketamine news

    Aggregate Study on the Efficacy of Ketamine to Treat Depression Shows Promising Results.

    Flow Integrative - Christi Myers

    Provider Spotlight – Christi Myers, Flow Integrative

    How To Help A Depressed Person

    How To Help A Depressed Person

  • Chronic Pain
    ER Doctor Aims for Patient Centered Breakthrough: A Ketamine That Works Orally

    ER Doctor Aims for Patient Centered Breakthrough: A Ketamine That Works Orally

    Ketamine: A Paradigm Shift in Pain Management

    Ketamine: A Paradigm Shift in Pain Management

    ketamine treatment for depression

    Amidst An Opioid Crisis, Ketamine Has the Potential To Save Lives

    Ketamine for pain

    Multi-Day Low Dose Ketamine Infusion For The Treatment Of Complex Regional Pain Syndrome

    ketamine for chronic pain

    End Chronic Back Pain with Ketamine for a Fuller Life

    ketamine for pain

    What You Should Know About Rheumatoid Arthritis

    ketamine for pain

    Myofascial Pain Syndrome: Symptoms, Causes, and Treatment

    ketamine for pain

    A sweet reprieve: Ketamine helps to relive phantom limb pain

  • PTSD
    ketamine news

    Dispelling the Stigmas, Ketamine, and the Future of Mental Healthcare

    ketamine news

    A First of its Kind: Wellbeing Digital Sciences Delivers its “First Ketamine Treatment Under the Inpatient KITE Program”

    veterans day

    Veterans’ Day: What Does PTSD Look Like In Veterans?

    PTSD awareness month

    PTSD Awareness Month: What Can I Do To Help?

    Trump Orders ‘a lot’ of Ketamine for Depressed Veterans

    Will Ketamine Be A Breakthrough Drug for PTSD?

    Ketamine to treat ptsd

    PTSD Sufferers ‘Healed’ With New Ketamine Infusion Therapy?

    ketamine to treat PTSD

    VA Uses Ketamine To Treat PTSD Effectively

    ketamine to treat ptsd

    Ketamine can help treat PTSD

  • Video
  • Ketamine Directory
  • Ketamine Media
  • Contact
No Result
View All Result
  • Home
  • Depression
    ketamine news

    Bronner’s Magic Soaps Becomes The First Company to Offer Ketamine-Assisted Therapy as Part of Employees’ Health Benefits

    ketamine news

    Popular Soap Company–Dr. Bronner’s– Plans To Explore The Psychedelic Space

    ketamine news

    Psychedelic and Plant Medicine Decriminalization Efforts Spread to the Midwest.

    ketamine news

    What There is to Know About Ketamine vs. Electroconvulsive Therapy (ECT)

    ketamine news

    Dispelling the Stigmas, Ketamine, and the Future of Mental Healthcare

    ketamine news

    A First of its Kind: Wellbeing Digital Sciences Delivers its “First Ketamine Treatment Under the Inpatient KITE Program”

    ketamine news

    Aggregate Study on the Efficacy of Ketamine to Treat Depression Shows Promising Results.

    Flow Integrative - Christi Myers

    Provider Spotlight – Christi Myers, Flow Integrative

    How To Help A Depressed Person

    How To Help A Depressed Person

  • Chronic Pain
    ER Doctor Aims for Patient Centered Breakthrough: A Ketamine That Works Orally

    ER Doctor Aims for Patient Centered Breakthrough: A Ketamine That Works Orally

    Ketamine: A Paradigm Shift in Pain Management

    Ketamine: A Paradigm Shift in Pain Management

    ketamine treatment for depression

    Amidst An Opioid Crisis, Ketamine Has the Potential To Save Lives

    Ketamine for pain

    Multi-Day Low Dose Ketamine Infusion For The Treatment Of Complex Regional Pain Syndrome

    ketamine for chronic pain

    End Chronic Back Pain with Ketamine for a Fuller Life

    ketamine for pain

    What You Should Know About Rheumatoid Arthritis

    ketamine for pain

    Myofascial Pain Syndrome: Symptoms, Causes, and Treatment

    ketamine for pain

    A sweet reprieve: Ketamine helps to relive phantom limb pain

  • PTSD
    ketamine news

    Dispelling the Stigmas, Ketamine, and the Future of Mental Healthcare

    ketamine news

    A First of its Kind: Wellbeing Digital Sciences Delivers its “First Ketamine Treatment Under the Inpatient KITE Program”

    veterans day

    Veterans’ Day: What Does PTSD Look Like In Veterans?

    PTSD awareness month

    PTSD Awareness Month: What Can I Do To Help?

    Trump Orders ‘a lot’ of Ketamine for Depressed Veterans

    Will Ketamine Be A Breakthrough Drug for PTSD?

    Ketamine to treat ptsd

    PTSD Sufferers ‘Healed’ With New Ketamine Infusion Therapy?

    ketamine to treat PTSD

    VA Uses Ketamine To Treat PTSD Effectively

    ketamine to treat ptsd

    Ketamine can help treat PTSD

  • Video
  • Ketamine Directory
  • Ketamine Media
  • Contact
No Result
View All Result
ketamine.news
Home Featured

The Fed Just Became A Little More Psychedelic.

John Hopkins Center for Psychedelic and Consciousness Research Receives the First Federal Psychedelics Funding in 50 Years.

David Connell by David Connell
March 17, 2022
in Featured, Mental Health, Psychedelic Medicine
0
ketamine news
0
SHARES
64
VIEWS
Share on FacebookShare on Twitter

By David Connell, Ketamine News
Thursday, March 17, 2022

John Hopkins University has always been a leader in the research and development of novel new psychotherapy treatments. Now their prestigious Center of Psychedelics and Consciousness Research will be at the forefront of research into the possible use of the classical psychedelic compound Psilocybin to treat depression.

Psilocybin, for those unfamiliar with the drug, is a chemical found in the Psilocybe family of mushrooms (aka magic mushrooms). While not psychoactive on its psilocybin is the precursor to psilocin, the psychoactive drug responsible for inducing altered states of consciousness in those that consume it.

While psilocybin has been well known and used in Native American cultures for millennia as a sacred and spiritual medicine, its use in the 1960s by the counter culture movement saw it outlawed under the Nixon administration in 1970 as part of the Federal Controlled Substances Act. Along with other classic psychedelics like LSD (lysergic acid diethylamide), DMT (dimethyltryptamine), Peyote, and later MDMA (methylenedioxymethamphetamine).

The ban effectively halted research into several of these drugs, which Psychiatrists of the time saw as breakthrough treatments for various mental health conditions. Until its passage, disorders like post-partum depression, bipolar disorder, and treatment-resistant depression had seen a significant quantity of experimental treatment using both LSD and psilocybin.

John Hopkins Receives $4 Million in Federal Grants to Research Psychedelic-Medicine.

Fortunately for researchers at John Hopkins and across the nation, it seems that the Federal Government is slowly beginning to shift its stance on at least a few of these compounds. By awarding $4 million in funding to John Hopkins, the fed takes its first tentative steps towards what researchers hope will be the eventual rescheduling and legalization of certain psychedelic compounds for therapeutic use.

The historical importance of this grant is monumental,” says principal investigator Matthew Johnson, Ph.D., Susan Hill Ward Professor in Psychedelics and Consciousness in the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine.

Dr. Matthew Johnson of John Hopkins University School of Medicine believes that this shift was bound to happen. A growing body of research accumulated over the last 20 years has repeatedly shown that psilocybin and, thus, psilocin is incredibly safe and has significant potential for treating conditions such as depression and end-of-life anxiety, PTSD, and addiction.

Findings from research conducted by the National Institute of Drug Abuse, the National Institutes of Health, The Imperial College of London, and the Multidisciplinary Association for Psychedelics Studies support these studies.

Although John Hopkins Center of Psychedelics and Consciousness Research is the first organization to receive a federal grant for psychedelics research in 20 years, many other organizations continue to add new studies to a growing roster of work indicating psychedelics could provide novel treatments for psychological issues.

MAPS, for example, is entering Phase 3 Clinical trials for the treatment of severe Post Traumatic Stress Disorder (PTSD). In 2018 Compass Pathways, NASDAQ: CMPS, received an FDA Breakthrough Therapy designation for their use of psilocybin therapy to combat treatment-resistant depression. They are currently in Phase 2b of their clinical trials. Other companies like Revitalist, CSE: CALM now offer ketamine infusions and injections paired with therapy to treat depression, PTSD, bipolar disorder, and others.

With the dizzying number of companies entering the psychedelic-medicine front, it is no wonder that experts like MAPS founder Rick Doblin believe that FDA approval and legalization of drugs like MDMA and Psilocybin will happen in the next several years.

David Connell is a U.S. Air Force Veteran writer and author of Cooking with Magic: The Psilocybin Cookbook. David holds a B.A. in Communications and Creative Writing from the University of Tennessee, Knoxville. Connect with him about drug policy reform, his thoughts on research in novel psychedelic therapies, creative writing, and his unabashed love for Science Fiction on Twitter, LinkedIn, and Instagram.

Sources:

Gabay, M. (2013, June). The Federal Controlled Substances Act: Schedules and Pharmacy Registration. Hospital pharmacy. Retrieved November 8, 2021, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839489/.

Johns Hopkins Medicine receives first federal grant for psychedelic treatment research in 50 Years. Johns Hopkins Medicine Newsroom. (2021, October 18). Retrieved Nov 8, 2021, www.hopkinsmedicine.org/news/newsroom/news-releases/johns-hopkins-medicine-receives-first-federal-grant-for-psychedelic-treatment-research-in-50-years.

Phase 3 program: MDMA-Assisted therapy for PTSD. MAPS. (n.d.). Retrieved November 8, 2021, from https://maps.org/research/mdma/ptsd/phase3.

Robhern. (2020, March 2). Treatment-resistant depression study: Depression clinical trials. Compass Pathways. Retrieved November 8, 2021, from https://compasspathways.com/our-research/psilocybin-therapy/clinical-trials/treatment-resistant-depression/.

Tags: Psychedelicpsychedelic medicine
Previous Post

Psychedelic and Plant Medicine Decriminalization Efforts Spread to the Midwest.

Next Post

Popular Soap Company–Dr. Bronner’s– Plans To Explore The Psychedelic Space

Next Post
ketamine news

Popular Soap Company–Dr. Bronner’s– Plans To Explore The Psychedelic Space

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Browse by Category

  • A Day in the Life
  • Esketamine
  • Featured
  • Ketamine Dictionary
  • Ketamine for Anxiety
  • Ketamine for Depression
  • Ketamine for Pain
  • Ketamine for PTSD
  • Ketamine in The News
  • Mental Health
  • Psychedelic Medicine
  • Suicide Prevention
  • Uncategorized
ketamine news
Privacy Policy | Terms and Conditions

Categories

  • A Day in the Life
  • Esketamine
  • Featured
  • Ketamine Dictionary
  • Ketamine for Anxiety
  • Ketamine for Depression
  • Ketamine for Pain
  • Ketamine for PTSD
  • Ketamine in The News
  • Mental Health
  • Psychedelic Medicine
  • Suicide Prevention
  • Uncategorized

Recent Posts

  • Connecticut Approves a Bill That Could Pave Way for the Use of Psychedelic Substances to Treat Mental Health Illnesses
  • A Group of D.C. Advocacy Groups Have Joined Hands to Push For Drug Policy Reform in the Nation’s Capital
  • ‘Magic Mushrooms’ Look Set to Follow in the Footsteps of Cannabis
  • Bronner’s Magic Soaps Becomes The First Company to Offer Ketamine-Assisted Therapy as Part of Employees’ Health Benefits
  • Rhode Island Lawmakers Accelerate Drug Decriminalization Efforts
  • Chronic Pain
  • Contact
  • Depression
  • Home
  • Privacy Policy
  • PTSD
  • Terms and Conditions
  • Video

© 2022 Ketamine News

No Result
View All Result
  • Home
  • Depression
  • Chronic Pain
  • PTSD
  • Video
  • Ketamine Directory
  • Ketamine Media
  • Contact

© 2022 Ketamine News

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In